Control of spontaneous ovarian tumors by CD8+ T cells through NKG2D-targeted delivery of antigenic peptide

Cell and Bioscience

Volumn 3, Issue 1, 2013, Pages

  Kang, Tae H ^a   Knoff, Jayne ^b   Yang, Benjamin ^b   Tsai, Ya Chea ^b   He, Liangmei ^b   Hung, Chien Fu ^b,c   Wu, T C ^b,c  

^a Konkuk University   (South Korea)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Immunotherapy; NKG2D; Ovarian cancer; T cell adoptive transfer; TgMISIIR TAg transgenic mice

Indexed keywords

ANIMALIA; MUS MUSCULUS;

EID: 84890468835     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/2045-3701-3-48     Document Type: Article

References (23)

1. Baum M, Ebb S, Brooks M. Biological fallout from trials of adjuvant tamoxifen in early ovarian cancer. Adjuvant Ther Cancer 1990, 6:269-274.
2. Swain SM. Selection of therapy for stage III breast cancer. Surg Clin North Am 1990, 70:1061-1080.
3. Sznol M, Holmlund J. Antigen-specific agents in development. Semin Oncol 1997, 24:173-186.
4. Kang TH, Ma B, Wang C, Wu TC, Hung CF. Targeted coating with antigenic peptide renders tumor cells susceptible to CD8(+) T cell-mediated killing. Mol Ther: J Am Soc Gene Ther 2013, 21:542-553.
5. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE, Hellstrom I. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999, 96:11531-11536. 10.1073/pnas.96.20.11531, 18068, 10500211.
6. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004, 10:3937-3942. 10.1158/1078-0432.CCR-03-0801, 15217923.
7. Coppola JM, Bhojani MS, Ross BD, Rehemtulla A. A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia 2008, 10:363-370. 2288536, 18392131.
8. Page RE, Klein-Szanto AJ, Litwin S, Nicolas E, Al-Jumaily R, Alexander P, Godwin AK, Ross EA, Schilder RJ, Bassi DE. Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol 2007, 29:289-299.
9. Mercapide J, Lopez De Cicco R, Bassi DE, Castresana JS, Thomas G, Klein-Szanto AJ. Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness. Clin Cancer Res 2002, 8:1740-1746.
10. Bassi DE, Mahloogi H, Al-Saleem L, Lopez De Cicco R, Ridge JA, Klein-Szanto AJ. Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog 2001, 31:224-232. 10.1002/mc.1057, 11536372.
11. Cheng M, Watson PH, Paterson JA, Seidah N, Chretien M, Shiu RP. Pro-protein convertase gene expression in human breast cancer. Int J Cancer 1997, 71:966-971. 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.0.CO;2-4, 9185698.
12. Schalken JA, Roebroek AJ, Oomen PP, Wagenaar SS, Debruyne FM, Bloemers HP, Van de Ven WJ. Fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas. J Clin Invest 1987, 80:1545-1549. 10.1172/JCI113240, 442422, 2824565.
13. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immun 2003, 3:781-790.
14. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008, 27:5944-5958. 10.1038/onc.2008.272, 18836475.
15. Kang TH, Mao CP, He L, Tsai YC, Liu K, La V, Wu TC, Hung CF. Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects. PLoS One 2012, 7:e35141. 10.1371/journal.pone.0035141, 3324421, 22509395.
16. Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 2005, 106:1544-1551. 10.1182/blood-2004-11-4365, 1895219, 15890688.
17. Choi JH, Choi KC, Auersperg N, Leung PCK. Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 2004, 89:5508-5516. 10.1210/jc.2004-0044, 15531506.
18. Ramakrishna V, Negri DRM, Brusic V, Fontanelli R, Canevari S, Bolis G, Castelli C, Parmiani G. Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA'Äêrestricted cytotoxic T cells. Int J Cancer 1997, 73:143-150. 10.1002/(SICI)1097-0215(19970926)73:1<143::AID-IJC22>3.0.CO;2-G, 9334822.
19. Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I, Cliby WA. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Gynecol Oncol 2008, 108:141-148. 10.1016/j.ygyno.2007.09.010, 17988723.
20. Durrant LG, Pudney VA, Spendlove I. Using monoclonal antibodies to stimulate antitumor cellular immunity. Expert Rev Vaccines 2011, 10:1093-1106. 10.1586/erv.11.33, 21806402.
21. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003, 63:1389-1397.
22. Quinn BA, Xiao F, Bickel L, Martin L, Hua X, Klein-Szanto A, Connolly DC. Development of a syngeneic mouse model of epithelial ovarian cancer. J Ovarian Res 2010, 3:24. 10.1186/1757-2215-3-24, 2974672, 20958993.
23. Hung CF, Tsai YC, He L, Wu TC. Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther 2007, 14:921-929. 10.1038/sj.gt.3302913, 3183576, 17377599.